Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. BRZE

Go back to Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology (KURA) PT Lowered to $32 at H.C. Wainwright

November 24, 2021 10:20 AM EST

H.C. Wainwright analyst Joseph Pantginis lowered the price target on Kura Oncology (NASDAQ: KURA) to $32.00 (from $43.00) while maintaining a Buy rating.

The analyst commented, "This morning, Kura announced the FDA has placed a partial clinical hold on the KOMET-001 Phase 1b study evaluating KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML). The hold was put in place... More